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Abstract 
The trans-sialidase protein expressed by Trypanosoma cruzi is an important enzyme in the life cycle of 
this human pathogenic parasite and is considered a promising target for the development of new drug 
treatments against Chagas’ disease. Here we describe -amino phosphonates as a novel class of 
inhibitor of T. cruzi trans-sialidase. Molecular modelling studies were initially used to predict the 
active-site binding affinities for a series of amino phosphonates, which were subsequently synthesised 
and their IC50s determined in vitro. The measured inhibitory activities show some correlation with the 
predictions from molecular modelling, with 1-napthyl derivatives found to be the most potent 
inhibitors having IC50s in the low micromolar range. Interestingly, kinetic analysis of the mode of 
inhibition demonstrated that the -aminophosphonates tested here operate in a non-competitive 
manner. 
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1. Introduction  
Trans-sialidase (TcTS) is a crucial enzyme in the life cycle of the protozoan parasite 
Trypanosoma cruzi, the causative agent of Chagas’ disease [1 - 3]. T. cruzi is unable to synthesise sialic 
acid de novo, so TcTS functions to sequester sialic acid from host cell surfaces and transfer it to mucins 
on the surface of the parasite [4, 5]. The process of surface sialylation plays an important role in the 
pathogenicity of T. cruzi, by facilitating its invasion into host cells and helping to mask itself from the 
host immune system [6 - 9]. For these reasons, TcTs is considered a promising drugable target, with 
considerable effort being put into the discovery of trans-sialidase inhibitors as potential therapeutics 
for the treatment of Chagas’ disease [10 - 11]. 
 The 3-D structure and enzymatic mechanism of TcTS have been studied extensively. TcTS 
belongs to the glycoside hydrolase family GH33 (CaZY) [12], which contains most of the prokaryotic 
and some eukaryotic sialidases. Despite its inclusion in a glycoside hydrolase family, the predominant 
function of TcTS is trans-glycosidation, where -2,3-linked sialic acid residues are preferentially 
transferred between galactose residues on glycoconjugates [13 - 15]. This trans-glycosidation reaction 
has been demonstrated to operate through a double-displacement mechanism utilising a tyrosine 
residue as the catalytic nucleophile and displays classical ping-pong reaction kinetics [16 - 18].  
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The catalytic domain of TcTS comprises a six-bladed beta propeller topology, also observed 
with viral, bacterial and human sialidases [19]. Similarly, the active site of TcTS is highly conserved 
amongst members of the sialidase super family (GH33, 34 and 83) comprising eight strictly conserved 
amino acids which span three distinct binding motifs, the sialic acid, carboxylate and lactose binding 
sites (Fig. 1a) [17, 19].  Studies into the design of inhibitors of TcTS have investigated derivatives 
targeted towards all three of these binding motifs, either individually, or in combination [10]. 
Compounds based on derivatives of sialic acid have been found generally to be very poor inhibitors of 
TcTS. DANA (1) (Fig. 1b) is a low micromolar inhibitor of influenza neuraminidases, however was found 
to be only a weak inhibitor of TcTS (Ki = 12.3 mM) [20]. Compounds binding to the lactose site have 
shown more promise as inhibitors, such as the pentasaccharide Galp(1→2)[Galp(1→3)]Galp(1→6) 
[Galf(1→4)]GlcNAc-4)]GlcNAcol  with an IC50 of 0.61 mM towards TcTS [21]. Also, the reduced 
disaccharide lactitol (2) (Fig. 1b) was shown to inhibit TcTS with a KM = 0.26 mM and was also shown 
to reduce infection of mammalian cells [22]. Compounds incorporating a phosphonate group such as 
3 (IC50 = 5 mM) [23] and 4 (Ki = 7.3 mM) [24] have also been investigated in attempts to improve affinity 
to the carboxylate binding Arg triad, but have been found to be only weak inhibitors. Alternatively, 
the most potent inhibitors of TcTS found to date are not carbohydrate based at all, but instead contain 
multiple aromatic rings such as the anthraquinone (5) [25] and chalcone (6) [26] with Ki = 0.89 M and 
IC50 = 0.9 M, respectively (Fig. 1b). Interestingly, compounds 4 and 5, which contain aromatic rings, 
were both found to inhibit TcTS in a non-competitive manner. 
 Here we describe the design, synthesis and kinetic evaluation of a series of aryl -
aminophosphonates as inhibitors of TcTS. These compounds were designed to target all three binding 
motifs of the trans-sialidase (sialic acid, carboxylate and lactose), but incorporate substituted aromatic 
residues to occupy the carbohydrate binding regions, which simplifies their chemical synthesis 
significantly.  
 
4 
 
a)  
 
b)   
Fig. 1. a) Active site of TcTS with sialyl lactose bound (PDB; 1S0I) showing the strictly conserved amino acids that 
define the sialic acid, carboxylate and lactose binding regions. b) Structures of known inhibitors of TcTS and their 
reported inhibitory activities. 
 
2. Results and Discussion 
2.1. Molecular docking studies 
Molecular docking simulations were performed using AutoDock Vina [27] to 
investigate potential binding modes of a series of aryl -aminophosphonates in the active site 
of TcTS and to predict the impact of substitutions to the aromatic rings of groups X- and Y-, 
designed to bind to the sialic acid and lactose binding sites, respectively (Table 1). The 
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crystallised structure of TcTS chosen to perform the docking studies on was 1S0I (PDB code) 
[17] which is a complex (soaked) of trans-sialidase with the substrate -(2,3)-sialyl lactose. It 
was considered important to use a structure representing the Michaelis complex, where 
residue Tyr119 has rotated into the ‘closed’ binding conformation, in order to evaluate 
potential π-π stacking interactions in the lactose binding site. Additionally, as the -carbon of 
the proposed aminophosphonates is chiral, docking studies were performed on both the (R)- 
and (S)- isomers of each derivative to evaluate the preferred stereochemistry.  
Table 1.  
Predicted binding energies (kcal/mol) of the (R)- and (S)- isomers of -aminophosphonates 7a-7k using 
AutoDock Vina [27]. 
 
 
 
Compound X Y 
Predicted affinity 
(kcal/mol) 
(R)-isomer (S)-isomer 
7a 
phenyl 
phenyl -4.5 -3.8 
7b 1-napthyl -8.6 -7.0 
7c 2-napthyl -6.8 -5.6 
7d 2-biaryl -4.8 -3.6 
7e 3-biaryl -4.6 -3.7 
7f 4-methoxy phenyl 
1-napthyl 
-8.9 -7.4 
7g 4-chloro phenyl -8.8 -7.7 
7h 4-trifluoromethyl phenyl -7.5 -6.6 
7i 4-N-acetamido phenyl -9.6 -8.1 
7j 4-nitro phenyl -9.8 -8.0 
7k 3,5-di-trifluoromethyl phenyl -8.2 -7.6 
  
 Initially, X was fixed as a phenyl group (sterically conservative in comparison to sialic 
acid) and a series of Y = aryl derivatives screened for their predicted binding in the lactose 
site. The phenyl, naphthyl and bi-aryl Y groups were chosen to investigate the importance 
towards binding of number of aromatic groups, planarity and regiochemistry of attachment. 
For all derivatives at Y modelled (7a-7e), docking studies predict the (R)-isomer to form 
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slightly more favourable binding interactions with TcTS (Table 1). The 1-napthyl derivative (R)-
7b was predicted to bind most tightly (-8.6 kcal/mol), indicating that a planar group consisting 
of two aromatic residues is preferred. The predicted binding position of (R)-7b is presented 
in Fig. 2a, showing the phosphonate group occupying the carboxylate binding pocket (Arg 
triad), while the phenyl group (X) occupies the sialic acid binding site and the napthyl group 
(Y) occupies the lactose binding site, capable of forming π-stacking interactions between 
Tyr119 and Trp312. 
 Based on the initial docking results, Y was then fixed as a 1-napthyl group and the X 
position screened using a series of modified phenyl derivatives for predicted binding to the 
sialic acid site. Again, the predicted binding energies for all modelled derivatives 7a-7f slightly 
favoured the (R)- isomer. Encouragingly, the 4-N modified phenyl derivatives (R)-7d and (R)-
7e, which more resemble 4-N-acetyl neuraminic acid, were predicted to bind with the highest 
affinities of -9.6 and -9.8 kcal/mol, respectively (Table 1). An overlay of the predicted binding 
position of compounds (R)-7a-7f is shown in Fig. 2b. It can be seen that all derivatives, except 
for 7h (Fig. 2b: green sticks), are predicted to bind in a very similar position, with 7h predicted 
to have the poorest binding affinity. 
 
 
a)  b)  
Fig. 2. a) Predicted binding position of (R)-isomer of compound 7b (grey sticks) in the TcTS active site (side-
chains in blue sticks). b) Overlay of predicted binding positions for (R)-isomer of compounds 7f-7k in TcTS. 
 
7f
7g
7h
7i
7j
7k
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2.2. Chemistry 
 Each of the -aminophosphonates modelled in the docking experiments were then 
synthesised chemically to facilitate their biochemical evaluation as inhibitors of TcTS. One of 
the most convenient methods for the synthesis of -aminophosphonates is reported by 
Naydenova et al. [28] which uses a one-pot, solvent-free modification of the original 
Kabachnik-Fields reaction [29, 30]. Here, the relevant X-benzaldehyde and Y-amine 
derivatives were heated by microwave irradiation in dimethylphosphite to generate the 
respective -aminophosphonate dimethyl esters 8a-8k (Scheme 1). Treatment of the 
protected phosphonates 8a-8k with trimethylsilyl bromide then gave the target compounds 
7a-7k, which were isolated as racemates in generally good to excellent yields over the two 
steps (Table 2). Considerable attempts were made to isolate the products 8a-8k as pure 
enantiomers using methods such as co-crystallisation with chiral resolving agents and chiral 
HPLC. As none of these methods were successful in providing pure enantiomers (or even any 
enantiomeric enrichment), the kinetic evaluations were performed on the racemates. 
 
Scheme 1. Reagents and conditions: (a) Microwave (90W, time specified in Table 2), dimethylphosphite (10 
equiv. w/v). (b) TMSBr (equiv. specified in Table 2), CH2Cl2/DMF, 0°C, 30 minutes. X and Y are defined in Table 
1. 
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Table 2  
Specific reaction conditions and product yields for the synthesis of compounds 7a-7k. 
 
Compound 
Time 
(min) 
Yield of 8 
(%) 
TMSBr 
(equiv.) 
Yield of 7 
(%) 
7a 5 75 5 94 
7b 5 85 3 82 
7c 5 70 5 94 
7d 7 84 7.5 86 
7e 5 76 4.5 74 
7f 7 66 5 49 
7g 5 87 4.5 79 
7h 7 55 5 64 
7i 8 72 2.5 94 
7j 6 72 4.5 59 
7k 7 84 3.5 40 
 
 
2.3 Trans-sialidase inhibition studies 
The inhibitory activities of the newly synthesised -aminophosphonates 7a-7k were 
then evaluated by determining their IC50 values towards TcTS following methods described 
previously [31]. The assay employed uses 2’-(4-methylumbelliferyl)--D-N-acetylneuraminic 
acid (MuNANA) as the substrate to measure the hydrolytic activity of TcTS by detection of the 
fluorescent product of hydrolysis, 4-methylumbelliferone [19]. The IC50s determined for 
compounds 7a-7k are presented in Table 3. 
 For compounds 7a-7e, where the Y group was screened with the X group fixed as 
phenyl, some broad agreement was observed between the predicted binding energies and 
the IC50 values measured. The two napthyl derivatives 7b and 7c were predicted to bind most 
favourably with TcTS (-8.6 and -6.8 kcal/mol, respectively) for this set of compounds and both 
were indeed found to have the two lowest IC50s (0.47 and 0.51 mM, respectively). However, 
docking studies predicted essentially no difference between the binding energies of the two 
bi-aryl derivatives 7d and 7e, while the inhibition studies demonstrate a 10-fold difference 
between the observed IC50s of 0.63 mM and 5.58 mM, respectively.  
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Table 3 
Inhibitory values determined for compounds 7a-7k against TcTS. 
 
Compound 
IC50  
(mM)a 
Std. error 
(mM) 
Ki 
(mM) 
Mode of 
inhibition 
7a >7.5 b >20   
7b 0.47 ±0.09 0.43 Non-competitive 
7c 0.51 ±0.09   
7d 0.63 ±0.04   
7e 5.58 ±2.37   
7f 0.27 ±0.03   
7g 0.71 ±0.05   
7h 0.29 ±0.01   
7i 0.23 ±0.03 0.19 Non-competitive 
7j 0.21 ±0.04 0.14 Non-competitive 
7k 2.35 ±0.83   
a Data are expressed as the mean average of three (n=3) independent 
experiments. b Saturating concentrations could not be reached owing to 
solubility. 
 
 For the second set of compounds 7f-7k, where Y was fixed as a 1-napthyl group and 
derivatives screened for X, there was again mixed agreement between predicted binding 
energies and the observed IC50s. In general, compounds substituted at the 4-position of the 
pheny group (7f-7j) were all found to have comparable IC50 values (0.21 – 0.71 mM), while 
the 3,5-modified derivative 7k was found to be a significantly poorer inhibitor with an IC50 of 
2.35 mM. Notably, the 4-trifluoromethyl derivative 7h was predicted to be the poorest binder 
in docking studies, but its IC50 = 0.29 mM was found to be almost equivalent to the best 
inhibitors. 
 To determine whether -aminophosphonates display any selectivity for inhibition of 
TcTS over other family GH33 sialidases (which includes the human sialidases), we determined 
the IC50s of the most potent inhibitor, compound 7j, against the two bacterial sialidases 
Clostridium perfringens neuraminidase (CpNA) and Staphylococcus pneumoniae 
neuraminidase A (SpNA) (Supplementary Data). Compound 7j was found to be a poor 
inhibitor of both enzymes, with IC50s of 2.39 mM and 1.41 mM against SpNA and CpNA, 
respectively. As such, 7j displays 7 to 12 fold better inhibition against TcTS (IC50 0.21 mM) than 
the bacterial sialidases suggesting that -aminophosphonates possess some degree of 
selectivity for trans-sialidase. 
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In summary, the IC50 values determined here suggest that -aminophosphonates are 
effective inhibitors of TcTS and possess some selectivity for this enzyme over other family 
GH33 sialidases. Furthermore, derivatives consisting of Y groups containing at least two 
aromatic residues in a planar conformation and X groups modified at the C-4 position, possess 
the most potent inhibitory activities towards trans-sialidase. 
 
2.4 Mode of inhibition studies 
Having demonstrated that -aminophosphonates, as a class, are effective inhibitors of TcTS, 
the mode of inhibition of the parent 1-napthyl compound 7b and the two most potent 
compounds 7i and 7j were then investigated. Lineweaver-Burk plots were produced by 
plotting residual enzyme activity against substrate concentration for a series of inhibitor 
concentrations. The regression lines for each inhibitor concentration converge on the X-axis 
demonstrating that all three compounds display non-competitive inhibition kinetics towards 
TcTS (Fig. 3). The Ki values for 7b, 7i and 7j were determined to be 430 M, 190 M and 140 
M, respectively (Table 3). It is interesting to note that a number of inhibitors containing 
multiple aromatic rings, including 5, have been shown previously by other groups to display 
non-competitive inhibition kinetics towards TcTS [25].  
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Fig. 3. Plots of Lineweaver-Burk kinetics performed using [MuNANA] =  2.0, 1.0, 0.5, 0.2, 0.1, 0.05 and 0.01 mM 
for: a) Compound 7b at 0 (), 0.05 (), 0.10 (), 0.20 () and 0.40 () mM.  b) Compound 7i at 0 (), 0.02 (), 
0.05 (), 0.10 () and 0.15 () mM. c) Compound 7j at 0 (), 0.05 (), 0.10 () and 0.20 () mM. 
 
 
3. Conclusions 
 
 We have successfully synthesised a series of eleven aryl -aminophosphonates in two 
chemical steps in good to excellent overall yields. Several of these derivatives were 
demonstrated to inhibit TcTS in the low micromolar range, comparable to some of the most 
potent carbohydrate-based inhibitors of this enzyme. Furthermore, we have shown that 
these compounds display non-competitive inhibition kinetics towards TcTS, consistent with 
several other compounds containing multiple aromatic residues. Together, these results 
-0.01 0.00 0.01 0.02
0.05
0.10
0.15
0.20
1/[S] (mM-1)
1
/V
  
(µ
m
o
l/
m
in
)
-0.01 0.00 0.01 0.02
0.05
0.10
0.15
0.20
0.25
1/[S] (mM-1)
1
/V
  
(µ
m
o
l/
m
in
)
-0.01 0.00 0.01 0.02
0.05
0.10
0.15
0.20
0.25
1/[S] (mM-1)
1
/V
  
(µ
m
o
l/
m
in
)
a) 
b) 
c) 
12 
 
demonstrate that -aminophosphonates are a promising class of compounds for further 
development towards more potent inhibitors of T. cruzi trans-sialidase. 
 
4. Experimental protocols 
 
4.1. General methods and materials 
 
Chemical reagents were purchased from Sigma-Aldrich unless specifically stated. 
Anhydrous solvents were purchased from Sigma-Aldrich and used without further 
purification. Purified Clostridium perfringens neuraminidase (CpNA) was purchased from 
Sigma-Aldrich. All other solvents were purchased from Fisher Scientific. Analytical thin layer 
chromatography (TLC) was carried out on Merck aluminium backed TLC plates silica gel 60 
F254 (0.25 mm thickness), viewed using UV light of wavelength 254 nm or stained with 
potassium permanganate solution or para-anisaldehyde stain. Silica gel chromatography was 
performed on silica gel 60 Å (200-400 mesh) from Sigma-Aldrich. Preparative reverse phase 
chromatography (C-18) was performed using a VersaFlash hand held column (23 x 110 mm) 
from Supelco. Melting points were obtained using a Thermo Fisher IA9000 digital melting 
point apparatus. 1H, 13C and 31P NMR spectra were recorded using Bruker Advance III 400 MHz 
spectrometer with acquisition frequencies of 400 for 1H; 101 MHz for 13C; and 162 MHz for 
31P. Deuterated solvents were purchased from Cambridge Isotope Laboratories. The NMR 
chemical shifts δ were recorded in parts per million (ppm) with reference to tetramethylsilane 
for 1H and 13C and phosphoric acid for 31P NMR spectroscopy. High resolution mass 
spectrometry was performed using a BrukerMicrOTOF electrospray ionisation mass 
spectrometer. 
 
4.2 Molecular Docking 
A structure of TcTS obtained by X-ray diffraction with the ligand (2,3)-sialyl lactose 
bound (PDB code: 1S0I) was used for all docking studies. A model of the structure was 
prepared using AutoDock tools, which involved removing the bound ligand, mutating residue 
A59D, adding all hydrogens to the model, setting the lactose binding site residues Y119 and 
W312 to be flexible, and limiting the region of docking to the catalytic site. 3-D models of -
phosphonate ligands were built using Phenix eLBOW [32] or CCP4 JLigand [33]. Molecular 
docking experiments were run using AutoDock Vina [27] to screen for potential binding 
positions and to calculate the predicted binding energy as the docking score. 
 
4.3 General procedure for the synthesis of protected -aminophosphonates 8a-8k. 
 
A mixture of the aldehyde (4.7 mmol, 1 eq.) and the amine (4.7 mmol, 1 eq.) were 
dissolved in dimethylphosphite (10 equiv. w/v) and the resultant solution subjected to 
microwave heating (90 W) for the specified time (Table 2). The reaction mixture was then 
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diluted with dichloromethane, and the organic phase washed sequentially with saturated 
sodium bicarbonate solution and brine. The organic phases were then combined and dried 
over anhydrous magnesium sulphate, filtered and the filtrate concentrated. The resultant 
residue was then purified by column chromatography (35% EtOAc/petroleum ether) to give 
the protected -aminophosphonates 8a-8k. 
 
4.3.1 (±) Dimethyl-[-(phenyl)(phenylamino)methyl] phosphonate (8a) 
The title compound was prepared from benzaldehyde and aniline. White solid; yield 75%; 1H 
NMR (400 MHz, CDCl3): δ 7.50 – 7.40 (m, 2H, Ar), 7.35 – 7.27 (m, 2H, Ar), 7.27 – 7.18 (m, 1H, 
Ar), 7.12 – 7.01 (m, 2H, Ar), 6.66 (dd, J = 7.3, 1.1 Hz, 1H, Ar), 6.61 – 6.52 (m, 2H, Ar),  4.81-4.70 
(m, 2H, NH, P-CH ), 3.71 (d, J = 10.6 Hz, 3H, OMe), 3.43 (d, J = 10.6 Hz, 3H, OMe).13C NMR 
(100.6 MHz, CDCl3): δ 146.16, 136.12, 129.13, 128.65, 127.98, 127.76, 118.48, 113.85, 55.68 
(d, J = 151.3 Hz), 53.75, 53.69. 31P NMR (161.93 MHz, CDCl3): δ 24.96. HRMS (ESI): Calculated 
for C15H18NO3PNa (M+Na)+: m/z= 314.0922, found m/z = 314.0907. 
 
4.3.2 (±) Dimethyl-[-(phenyl)(napthalen-1-ylamino)methyl] phosphonate (8b) 
The title compound was prepared from benzaldehyde and 1-aminonapthalene. White solid; 
yield 85%; 1H NMR (400 MHz, CDCl3):  δ 8.06-8.03 (m, 1H, Ar), 7.79- 7.75 (m, 1H, Ar), 7.56 – 
7.45 (m, 4H, Ar), 7.38 – 7.19 (m, 5H, Ar), 6.49 – 6.37 (m, 1H, Ar), 5.49 (s, 1H, NH), 5.01 (d, J = 
19.8 Hz, 1H, P-CH), 3.80 (d, J = 10.6 Hz, 3H, OMe), 3.53 (d, J = 10.6 Hz, 3H, OMe). 13C NMR 
(101 MHz, CDCl3) δ 141.05, 135.25, 134.20, 128.72, 128.62, 128.07, 127.58, 126.13, 125.85, 
125.11, 123.88, 119.97, 118.69, 106.54, 55.87 (d, J = 151.0 Hz), 53.85, 53.81. 31P NMR (162 
MHz, CDCl3): δ 24.94. HRMS (ESI) calculated for C19H21NO3P [M+H]+: 342.1259. Found: 
342.1252. 
 
4.3.3 (±) Dimethyl-[-(phenyl)(napthalen-2-ylamino)methyl] phosphonate (8c) 
The title compound was prepared from benzaldehyde and 2-aminonapthalene. White solid; 
yield 70%; 1H NMR (400 MHz, CDCl3):  δ 8.03-8.01 (m, 1H, Ar), 7.78-7.76 (m, 1H, Ar), 7.53-7.45 
(m, 4H, Ar), 7.35-7.22 (m, 4H, Ar), 7.12-7.14 (m, 1H, Ar), 6.42-6.40 (m, 1H, Ar), 5.46 (s, 1H, 
NH), 4.97 (d, J = 21.5 Hz, 1H, P-CH), 3.78 (d, J = 10.8 Hz, 3H, OMe), 3.52 (d, J = 10.4, 3H, OMe). 
13C NMR (101 MHz, CDCl3) δ 141.12, 140.97, 135.24, 135.21, 134.20, 128.79, 128.76, 128.66, 
128.14, 128.12, 127.63, 127.57, 126.18, 125.91, 125.75, 125.16, 123.87, 120.02, 118.72, 
106.55, 56.33 (d, J = 149.6 Hz), 54.03, 53.96, 53.89. 31P NMR (162 MHz, CDCl3): δ 24.90. HRMS 
(ESI) calculated for C19H21NO3P [M+H]+: 342.1259. Found: 342.1250. 
 
4.3.4 (±) Dimethyl-[-(phenyl)([1,1'-biphenyl]-2-ylamino)methyl] phosphonate (8d) 
The title compound was prepared from benzaldehyde and 1,1’-biphenyl-2-amine. White solid; 
yield 76%; 1H NMR (400 MHz, CDCl3): δ 7.52 – 7.42 (m, 4H, Ar), 7.42 – 7.35 (m, 3H, Ar), 7.35 – 
7.29 (m, 2H, Ar), 7.28 – 7.24 (m, 1H, Ar), 7.13 – 7.05 (m, 2H, Ar), 6.80 – 6.75 (m, 1H, Ar), 6.55 
– 6.50 (m, 1H, Ar), 4.97 (s, 1H, NH), 4.78 (d, J = 24.2 Hz, 1H, P-CH), 3.62 (d, J = 10.6 Hz, 3H, 
OMe), 3.47 (d, J = 10.6 Hz, 3H, OMe). 13C NMR (100.6 MHz, CDCl3): δ 143.14, 138.88, 135.61, 
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130.25, 129.18, 128.92, 128.78, 128.62, 127.96, 127.62, 127.50, 118.28, 111.89, 56.13 (d, J = 
150.8 Hz), 53.69, 53.52. 31P NMR (162 MHz, CDCl3): δ 24.51. HRMS (ESI) calculated for 
C21H22NO3PNa [M+Na]+: 390.1235. Found: 390.1247. 
 
4.3.5 (±) Dimethyl-[-(phenyl)([1,1'-biphenyl]-3-ylamino)methyl] phosphonate (8e) 
The title compound was prepared from benzaldehyde and 1,1’-biphenyl-3-amino. White 
solid; yield 84%; 1H NMR (400 MHz, CDCl3): δ 7.49 – 7.42 (m, 2H, Ar), 7.42 – 7.37 (m, 2H, Ar), 
7.36 – 7.27 (m, 4H, Ar), 7.26 – 7.20 (m, 2H, Ar), 7.11 (t, J = 7.8 Hz, 1H, Ar), 6.87 (dd, J = 7.6, 1.7 
Hz, 1H, Ar), 6.79 (t, J = 2.0 Hz, 1H, Ar), 6.52 (dd, J = 8.2, 2.4 Hz, 1H, Ar),  5.22 (s, 1H, NH), 4.75 
(br d, J = 25.0 Hz, 1H, P-CH), 3.74 (d, J = 10.7 Hz, 3H, OMe), 3.43 (d, J = 10.6 Hz, 3H, OMe). 13C 
NMR (101 MHz, CDCl3) δ 146.42, 143.45, 142.02, 135.56, 129.49, 128.70, 128.52, 128.03, 
127.79, 127.73, 127.11, 126.96, 117.57, 112.81, 112.67, 55.71 (d, J = 151.4 Hz), 53.76, 53.69. 
31P NMR (162 MHz, CDCl3): δ 24.88. HRMS (ESI) calculated for C21H23NO3P [M+H]+: 368.1416. 
Found: 368.1416.  
 
4.3.6 (±) Dimethyl-[-(4-methoxyphenyl)(napthalen-1-ylamino)methyl] phosphonate (8f) 
The title compound was prepared from 4-methoxybenzaldehyde and 1-aminonapthalene. 
White solid; yield 66%; 1H NMR (400 MHz, CDCl3) δ 8.03-8.01 (m, 1H, Ar), 7.80-7.77 (m, 1H, 
Ar), 7.53-7.42 (m, 4H, Ar), 7.26-7.23 (m, 2H, Ar), 7.20-7.16 (m ,1H, Ar), 6.88 – 6.82 (m, 2H, Ar), 
5.90 (br s, 1H, NH), 4.93 (d, J = 24.6 Hz, 1H, P-CH), 3.80 (s, 3H, Ar-OMe), 3.79 (d, J = 10.5 Hz, 
3H, OMe), 3.55 (d, J = 10.5 Hz, 3H, OMe). 13C NMR (101 MHz, CDCl3) δ 157.3, 144.4, 134.21, 
128.73, 128.68, 128.59, 126.12, 125.80, 125.06, 123.93, 119.96, 118.65, 114.21, 114.18, 
106.62, 55.51 (d, J = 150.3 Hz), 53.80, 53.69, 34.52. 31P NMR (162 MHz, CDCl3): δ 25.12. HRMS 
(ESI) Calculated for C20H23NO4P [M+H]+: 372.1364. Found 372.1359.  
 
4.3.7 (±) Dimethyl-[-(4-chlorophenyl)(napthalen-1-ylamino)methyl] phosphonate (8g) 
The title compound was prepared from 4-chlorobenzaldehyde and 1-aminonapthalene. 
White solid; yield 87%; 1H-NMR (400 MHz, CDCl3): δ 8.02 - 7.99 (m, 1H, Ar), 7.81 - 7.77 (m, 1H, 
Ar), 7.55 - 7.44 (m, 4H, Ar), 7.33 - 7.30 (m, 2H, Ar), 7.27 – 7.24 (m, 1H, Ar), 7.19-7.15 (m, 1H, 
Ar), 6.38 – 6.35 (m, 1H, Ar), 5.42 (s, 1H, NH), 4.98 (d, J = 24 Hz, 1H, P-CH), 3.82 (d, J = 10.8 Hz, 
3H, OMe), 3.62 (d, J = 10.8 Hz, 3H, OMe). 13C NMR (101 MHz, CDCl3): δ 140.83, 140.69, 134.21, 
133.93, 133.89, 128.96, 128.93, 128.85, 128.68, 126.04, 125.96, 125.84, 123.85, 119.87, 
119.02, 106.59, 56.09 (d, J = 150.3 Hz, P-CH), 54.59, 54.08. 31P NMR (162 MHz, CDCl3): δ 24.10. 
HRMS (ESI) Calculated for C19H19ClNNaO3P [M+Na]+: 398.0688. Found 398.0674. 
 
4.3.8 (±) Dimethyl-[-(4-(trifluoromethyl)phenyl)(napthalen-1-ylamino)methyl] phosphonate 
(8h) 
The title compound was prepared from 4-trifluoromethylbenzaldehyde and 1-
aminonapthalene. White solid; yield 56%; 1H NMR (400 MHz, CDCl3): δ 8.01 (dd, J = 7.7, 1.7 
Hz, 1H, Ar), 7.79 (dd, J = 7.5, 2.0 Hz, 1H, Ar), 7.70 – 7.44 (m, 6H, Ar), 7.26 (d, J = 8.2 Hz, 1H, 
Ar), 7.15 (dd, J = 8.2, 7.6 Hz, 1H, Ar), 6.42 – 6.18 (m, 1H, Ar), 5.45 (s, 1H, NH), 5.02 (d, J = 24.4 
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Hz, 1H, P-CH), 3.81 (d, J = 10.7 Hz, 3H, OMe), 3.61 (d, J = 10.7 Hz, 3H, OMe). 13C NMR (101 
MHz, CDCl3): δ 141.85, 140.66, 140.16, 139.28, 135.37, 132.46, 128.88, 128.48, 127.92, 
126.43, 126.08, 125.65, 125.27, 124.36, 122.36, 120.07, 117.04, 58.31 (d, J = 153 Hz, P-CH), 
53.97, 53.67. 31P NMR (162 MHz, CDCl3): δ 23.95. HRMS (ESI) Calculated for C20H19F3NNaO3P 
[M+Na]+: 432.0952. Found 432.0942. 
 
4.3.9 (±) Dimethyl-[-(4-N-acetamidophenyl)(napthalen-1-ylamino)methyl] phosphonate (8i) 
The title compound was prepared from 4-N-acetamidobenzaldehyde and 1-
aminonapthalene. White solid; yield 72%; 1H NMR (400MHz, CDCl3): δ 8.00 (d, J = 6.4Hz, 1H, 
Ar), 7.83-7.71 (m, 1H, Ar), 7.53 - 7.71 (m, 6H, Ar), 7.25 (d, J = 8.0 Hz, 1H, Ar), 7.18 - 7.14 (m, 
1H, Ar), 6.41 (d, J = 6.0 Hz, 1H, Ar), 5.39 (s, 1H, NH), 4.97(d, J = 20 Hz, 1H, P-CH), 3.81 (d, J = 
10.4Hz, 3H, OMe), 3.57 (d, J = 9.6Hz, 3H, OMe), 2.15(s, 3H, NAc). 13C NMR (101 MHz, CDCl3): 
δ 163.63, 141.15, 141.06, 138.28, 134.37, 130.65, 128.85, 128.38, 128.07, 126.33, 126.07, 
125.37, 124.06, 123.33, 120.05, 119.04, 55.55 (d, J = 151 Hz, P-CH), 54.23, 54.07, 24.63. 31P-
NMR (162 MHz, CDCl3): δ 25.57. HRMS (ESI) Calculated for C21H23N2NaO4P [M+H]+: 421.1293. 
Found 421.1269. 
 
4.3.10 (±) Dimethyl-[-(4-nitrophenyl)(napthalen-1-ylamino)methyl] phosphonate (8j) 
The title compound was prepared from 4-nitrobenzaldehyde and 1-aminonapthalene. Yellow 
solid; yield 72%; 1H NMR (400 MHz, CDCl3): δ 8.24 – 8.10 (m, 2H, Ar), 8.05 – 7.92 (m, 1H, Ar), 
7.79 (dd, J = 7.6, 1.7 Hz, 1H, Ar), 7.74 – 7.64 (m, 2H, Ar), 7.59 – 7.44 (m, 2H, Ar), 7.30 – 7.20 
(m, 1H, Ar), 7.18 – 7.09 (m, 1H, Ar), 6.35 – 6.16 (m, 1H, Ar), 5.45 (s, 1H, NH), 5.06 (d, J = 24.8 
Hz, 1H, P-CH), 3.82 (d, J = 10.8 Hz, 3H, OMe), 3.66 (d, J = 10.8 Hz, 3H, OMe).  13C NMR (101 
MHz, CDCl3): δ 143.63, 143.28, 140.06, 134.32, 128.77, 128.43, 128.38, 126.16, 125.91, 
125.49, 123.92, 123.88, 123.84, 119.75, 119.53, 106.60, 55.41 (d, J = 151 Hz, P-CH) 54.21, 
53.93. 31P NMR (162 MHz, CDCl3): δ 23.26. HRMS (ESI) Calculated for C19H20N2O5P [M+H]+: 
387.1109. Found 387.1099.  
 
4.3.11 (±) Dimethyl-[-(3,5-bis(trifluoromethyl)phenyl)(napthalen-1-ylamino)methyl] 
phosphonate (8k) 
The title compound was prepared from 3,5-bis(trifluoromethyl)benzaldehyde and 1-
aminonapthalene. White solid; yield 84%. 1H NMR (400 MHz, CDCl3): δ 8.12 - 8.04 (m, 3H, Ar), 
7.83 (d, J = 8.2 Hz, 2H, Ar), 7.58-7.50 (m, 2H, Ar), 7.32 (d, J = 8.4 Hz, 1H, Ar), 7.21 (m, 1H, Ar), 
6.29 (d, J = 5.6 Hz, 1H, Ar), 5.48 (s, 1H, NH), 5.08 (d, J = 24.4 Hz, 1H, P-CH), 3.85 (d, J = 10.8 Hz, 
3H, OMe), 3.69 (d, J = 10.8 Hz, 3H, OMe). 13C NMR (101 MHz, CDCl3): δ 142.65, 140.15, 140.06, 
137.18, 133.27, 131.56, 128.95, 127.87, 126.23, 126.17, 125.37, 125.07, 124.76, 122.36, 
121.83, 120.05, 116.04, 56.35 (d, J = 153.3 Hz, P-CH), 54.07, 53.97. 31P NMR (162 MHz, CDCl3): 
δ 21.06. HRMS (ESI) Calculated for C21H19F6NO3P [M+H]+: 478.1006. Found 478.1003.  
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4.4 General procedure for the synthesis of -aminophosphonates 7a-7k. 
 
TMSBr (equiv. specified in Table 3) was added dropwise to a solution of the dimethyl -
aminophosphonate (100 mg, 1.0 equiv.) in anhydrous CH2Cl2/DMF (2:1, 3 mL) at 0°C and the 
mixture held at this temperature for 30 minutes. The solution was then allowed to warm to 
room temperature and concentrated in vacuo. The resultant residue was then diluted with 
water (2.5 mL), neutralized (aq. 1M NaOH) and purified by C-18 reverse phase 
chromatography (20-40 % MeOH/H2O) to give the title phosphonic acid. 
 
4.4.1 (±) -(phenyl)(phenylamino)methyl phosphonic acid (7a) 
The title compound was prepared from 8a. White solid; yield 94%. 1H NMR (400 MHz, CD3OD):  
δ 7.54 (d, J = 8.0 Hz, 2H, Ar), 7.25 - 7.20 (m, 2H, Ar), 7.12 - 7.09 (m, 1H, Ar), 7.03 - 6.89 (m, 2H, 
Ar), 6.60 - 6.44 (m, 3H, Ar), 4.49 (d, J = 21.6 Hz, 1H, P-CH). 13C NMR (101 MHz, CD3OD): δ 
150.25, 144.04, 129.62, 129.15, 128.62, 126.46, 117.34, 114.74, 60.64 (d, J = 130 Hz). 31P NMR 
(162 MHz, CD3OD): δ 16.46. HRMS (ESI): Calculated for C13H13NO3P [M-H]-:  262.0633. Found 
262.0633. 
 
4.4.2 (±) -(phenyl)(napthalen-1-ylamino)methyl phosphonic acid (7b) 
The title compound was prepared from 8b. White solid; yield 82%. 1H NMR (400 MHz, CD3OD): 
δ 8.32 (dd, J = 7.9, 1.5 Hz, 1H, Ar), 7.76 – 7.69 (m, 1H, Ar), 7.59 (dt, J = 8.0, 1.7 Hz, 2H, Ar), 7.52 
– 7.35 (m, 2H, Ar), 7.24 (dd, J = 8.4, 6.9 Hz, 2H, Ar), 7.19 – 7.01 (m, 3H, Ar), 6.32 (dd, J = 6.6, 
2.2 Hz, 1H, Ar), 4.64 (d, J = 21.3 Hz, 1H, P-CH). 13C NMR (101 MHz, CD3OD): δ 145.19, 143.55, 
135.87, 129.13, 129.07, 128.60, 127.42, 126.46, 126.24, 125.27, 124.96, 122.25, 116.77, 
106.31, 60.57 (d, J = 131 Hz). 31P NMR (162 MHz, CD3OD): δ 15.74. HRMS (ESI) calculated for 
C17H15NO3P [M-H]-: 312.0790. Found: 312.0796. 
 
4.4.3 (±) -(phenyl)(napthalen-2-ylamino)methyl phosphonic acid (7c) 
The title compound was prepared from 8c. White solid; yield 94%. 1H NMR (400 MHz, CD3OD): 
δ 7.61-7.48 (m, 4H, Ar), 7.36-7.34 (m, 1H, Ar), 7.24-7.21 (m, 3H, Ar), 7.14-7.03 (m, 3H, Ar), 
6.49 (s, 1H, Ar), 4.60 (d, J = 21.1 Hz, 1H, P-CH). 13C NMR (101 MHz, CD3OD): δ 145.28, 145.17, 
138.54, 134.52, 129.08, 128.42, 127.85, 127.81, 127.56, 127.29, 127.13, 126.62, 125.85, 
122.55, 118.87, 105.93, 57.43 (d, J = 130 Hz). 31P NMR (162 MHz, CD3OD): δ 15.95. HRMS (ESI) 
calculated for C17H15NO3P [M-H]-: 312.0790. Found: 312.0776. 
 
4.4.4 (±) -(phenyl)([1,1'-biphenyl]-2-ylamino)methyl phosphonic acid (7d) 
The title compound was prepared from 8d. White solid; yield 86%. 1H NMR (400 MHz, CD3OD): 
δ 7.65 – 7.57 (m, 2H, Ar), 7.57 – 7.46 (m, 4H, Ar), 7.40 – 7.30 (m, 1H, Ar), 7.26 (t, J = 7.6 Hz, 
2H, Ar), 7.12 (td, J = 7.2, 1.5 Hz, 1H, Ar), 7.02 – 6.90 (m, 2H, Ar), 6.60 (td, J = 7.4, 1.1 Hz, 1H, 
Ar), 6.50 (dd, J = 8.4, 1.0 Hz, 1H, Ar), 4.54 (d, J = 21.5 Hz, 1H, P-CH). 13C NMR (101 MHz, CD3OD) 
δ 150.62, 144.09, 143.43, 142.86, 130.06, 129.53, 129.23, 128.69, 127.86, 126.50, 116.19, 
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113.90, 113.38, 60.82 (d, J = 129.8 Hz). 31P NMR (162 MHz, CD3OD): δ 15.72. HRMS (ESI) 
calculated for C19H17NO3P [M-H]-: 338.0946. Found: 338.0962.  
 
 
4.4.5 (±) -(phenyl)([1,1'-biphenyl]-3-ylamino)methyl phosphonic acid (7e) 
The title compound was prepared from 8e. White solid; yield 74%. 1H NMR (400 MHz, CD3OD) 
δ 7.62 – 7.57 (m, 2H, Ar), 7.47 – 7.39 (m, 2H, Ar), 7.39 – 7.20 (m, 5H, Ar), 7.18 – 7.01 (m, 2H, 
Ar), 6.85 – 6.73 (m, 2H, Ar), 6.57 (dd, J = 8.2, 2.3 Hz, 1H, Ar), 4.51 (d, J = 21.5 Hz, 1H, P-CH). 13C 
NMR (101 MHz, CD3OD) δ 150.62, 144.09, 143.43, 142.86, 130.06, 129.53, 129.23, 128.69, 
127.86, 126.50, 116.19, 113.90, 113.38, 60.82 (d, J = 129.8 Hz). 31P NMR (162 MHz, CD3OD): δ 
16.28. HRMS (ESI) calculated for C19H17NO3P [M-H]-: 338.0946. Found: 338.0960. 
 
4.4.6 (±) -(4-methoxyphenyl)(napthalen-1-ylamino)methyl phosphonic acid (7f) 
The title compound was prepared from 8f. White solid; yield 49%. 1H NMR (400 MHz, CD3OD) 
δ 8.22-8.2 (m, 1H, Ar), 7.76-7.74 (m, 2H, Ar), 7.53-7.44 (m, 3H, Ar), 7.36-7.34 (m, 2H, Ar), 7.12-
7.10 (m, 2H, Ar), 6.38-6.36 (m, 1H, Ar), 4.68 (d, J = 21.0 Hz, 1H, P-CH), 3.69 (s, 3H, Ph-OMe).  
13C NMR (101 MHz, CD3OD): δ 157.08, 143.50, 143.20, 133.92, 128.73, 128.67, 128.27, 126.74, 
126.18, 125.06, 123.06, 120.64, 116.32, 113.40, 105.40, 58.14 (d, J = 130.0 Hz), 55.21. 31P 
NMR (162 MHz, CD3OD): δ 15.52. HRMS (ESI) calculated for C18H17NO4P [M-H]-: 348.0906. 
Found: 348.0902. 
 
4.4.7 (±) -(4-chlorophenyl)(napthalen-1-ylamino)methyl phosphonic acid (7g) 
The title compound was prepared from 8g. White solid; yield 79%. 1H-NMR (400 MHz, CD3OD): 
δ 8.41 – 8.30 (m, 1H, Ar), 7.78 – 7.67 (m, 1H, Ar), 7.65 – 7.52 (m, 2H, Ar), 7.50 – 7.35 (m, 2H, 
Ar), 7.27 – 7.17 (m, 2H, Ar), 7.14 – 6.98 (m, 2H, Ar), 6.25 (dd, J = 7.5, 1.4 Hz, 1H, Ar), 4.65 (d, J 
= 21.1 Hz, 1H, P-CH). 13C NMR (101 MHz, CD3OD): δ 156.76, 147.94, 146.89, 144.98, 144.01, 
132.43, 129.74, 129.50, 129.15, 126.64, 126.52, 125.37, 122.91, 122.40, 116.59, 106.32, 60.78 
(d, J = 130 Hz). 31P NMR (CD3OD, 162 MHz): δ 14.89. HRMS (ESI) calculated for C17H14ClNO3P 
[M-H]-: 346.0400. Found: 346.0414. 
 
4.4.8 (±) -(4-(trifluoromethyl)phenyl)(napthalen-1-ylamino)methyl phosphonic acid (7h) 
The title compound was prepared from 8h. White solid; yield 64%. 1H NMR (400 MHz, CD3OD): 
δ 8.40 (d, J = 8.2 Hz, 1H, Ar), 7.78 (d, J = 8.0 Hz, 2H, Ar), 7.76 – 7.68 (m, 1H, Ar), 7.57 – 7.37 
(m, 4H, Ar), 7.13 – 6.97 (m, 2H, Ar), 6.23 (dd, J = 7.1, 1.7 Hz, 1H, Ar), 4.74 (d, J = 21.2 Hz, 1H, 
P-CH). 13C NMR (101 MHz, CD3OD): δ 149.08, 145.05, 135.919, 129.43, 129.39, 129.17, 128.59, 
128.30, 127.63, 127.40, 126.37, 125.38, 125.26, 125.26, 125.08, 124.94, 122.29, 106.15, 61.44 
(d, J = 130 Hz). 31P NMR (162 MHz, CD3OD): δ 14.50. HRMS (ESI) calculated for C18H14F3NO3P 
[M-H]-: 380.0663. Found: 380.0679.    
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4.4.9 (±) -(4-N-acetamidophenyl)(napthalen-1-ylamino)methyl phosphonic acid (7i) 
The title compound was prepared from 8i. White solid; yield 94%. 1H NMR (400 MHz, CD3OD): 
δ 8.34 (d, J = 8.4 Hz, 1H, Ar), 7.67 (d, J = 10.4 Hz, 1H, H-Ar), 7.54-7.51 (m, 2H, Ar), 7.41-7.33 
(m, 4H, Ar), 7.04-6.95 (m, 2H, Ar), 6.26 (d, J = 7.6 Hz, 1H, Ar), 4.63 (d, J = 20.8 Hz, 1H, P-CH), 
2.063 (s, 3H, Me). 13C NMR (101 MHz, CD3OD): δ 171.41, 145.16, 139.97, 137.05, 135.76, 
129.19, 129.15, 129.04, 127.33, 126.17, 125.16, 122.17, 121.02, 116.70, 106.25, 60.77 (d, J = 
129.6 Hz), 23.61. 31P NMR (162 MHz, CD3OD): δ 15.94. HRMS (ESI) calculated for C19H18N2O4P 
[M-H]-: 369.1004. Found: 369.1016. 
 
4.4.10 (±) -(4-nitrophenyl)(napthalen-1-ylamino)methyl phosphonic acid (7j) 
The title compound was prepared from 8j. Yellow solid; yield 59%. 1H NMR (400 MHz, CD3OD): 
δ 8.40 (d, J = 8.3 Hz, 1H, Ar), 8.12 (d, J = 8.4 Hz, 2H, Ar), 7.82 (dd, J = 8.8, 2.0 Hz, 2H, Ar), 7.72 
(d, J = 8.0 Hz, 1H, Ar), 7.53 – 7.39 (m, 2H, Ar), 7.07 (d, J = 4.3 Hz, 2H, Ar), 6.21 (t, J = 4.3 Hz, 1H, 
Ar), 4.81 (d, J = 21.3 Hz, 1H, P-CH). 13C NMR (101 MHz, CD3OD): δ 153.26, 147.42, 147.39, 
144.81, 144.69, 135.93, 129.74, 129.70, 129.25, 127.34, 126.56, 125.27, 123.91, 122.20, 
117.49, 106.22, 61.68 (d, J = 130 Hz). 31P NMR (162 MHz, CD3OD): δ 14.02. HRMS (ESI) 
calculated for C17H14N2O5P [M-H]-: 357.0640. Found: 357.0635. 
 
4.4.11 (±) -(3,5-bis(trifluoromethyl)phenyl)(napthalen-1-ylamino)methyl phosphonic acid 
(7k) 
The title compound was prepared from 8k. White solid; yield 40%. 1H NMR (400 MHz, CD3OD): 
δ 8.39 (d, J = 8.2 Hz, 1H, Ar), 8.18 (s, 2H, Ar), 7.77 – 7.58 (m, 2H, Ar), 7.56 – 7.32 (m, 2H, Ar), 
7.06 (d, J = 6.1 Hz, 2H, Ar), 6.14 (dd, J = 6.1, 2.7 Hz, 1H, Ar), 4.75 (d, J = 20.8 Hz, 1H, P-CH).13C 
NMR (101 MHz, CD3OD): 148.35, 148.30, 144.79, 135.94, 131.82, 131.47, 131.15, 129.32, 
129.20, 127.34, 126.75, 126.74, 126.52, 125.28, 124.09, 122.27, 122.07, 117.54, 105.93, 61.43 
(d, J = 130 Hz). 31P NMR (162 MHz, CD3OD): δ 13.55. HRMS (ESI) calculated for C19H13F6NO3P 
[M-H]-: 448.0537. Found: 448.0566.   
 
4.5 Protein expression and purification 
The plasmid pTrcHisA was used for expression of TcTS as described previously by Paris et al. 
[31]. This plasmid encodes for recombinant TcTS truncated to only contain the catalytic and 
lectin-like domains, with seven surface point mutations (N58F, S495K, V496G, E520K, D593G, 
I597D and H599R). These mutation were introduced to promote crystallisation and have been 
shown to have no impact on catalytic activity of TcTS [19].  Over expression was performed 
using E. coli strain BL21 (DE3) chemically competent cells (NEB). 
 
4.6 IC50 inhibition studies 
The hydrolytic activity of TcTS was determined using a continuous fluorometric assay by 
measuring the rate of release of 4-methylumbelliferone from the substrate 2’-(4-
methylumbelliferyl)--D-N-acteylneuraminic acid (MuNANA) as described previously [19]. 
Fluorescence was measured on a FLUOstar Omega (BMG labtech) using excitation and 
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emission filters at 360 and 460 nm, respectively. All assays were run in 20mM Tris-HCl and 
50mM NaCl at pH 7.5, containing 0.01% Triton X100 at 35°C. TcTS (50 g/mL) was pre-
incubated with each compound over at least seven inhibitor concentrations (ranging from 1 
M to 15 mM) for 10 minutes at 35°C, then the assay initiated by the addition of MuNANA 
(200 M) to give a final reaction volume of 100 L. The fluorescence was analysed using MARs 
data analysis software (BMG labtech), where a linear region of the raw data curve was 
selected and the slope calculated (RFU/min) which represents hydrolytic activity of the 
enzyme. The IC50 values were determined as the concentration of inhibitor required to reduce 
hydrolytic activity of TcTS by 50% compared to the control (no inhibitor). All assays were 
repeated in three (n=3) independent experiments. 
 
4.7 Mode of inhibition studies 
The Ki determinations were performed by measuring the residual activity of TcTS in the 
presence of several different concentrations of MuNANA (0–400 M) at specified inhibitor 
concentrations. Residual hydrolytic activity of TcTS was determined using the assay method 
described above. Nonlinear fitting was performed by GraphPad Prism software and Km/Vmax 
of different concentration of inhibitors was calculated. Further Ki and its standard error were 
calculated using competitive, non-competitive, uncompetitive and mixed inhibition models, 
the best fitting model were selected as the inhibition mode of the inhibitors. Lineweaver-Burk 
plots were generated from the reciprocals of both substrate concentration and activity at 
each inhibitor concentration to present the mode of inhibition. 
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